INTRODUCTION
============

Inflammatory bowel diseases (IBDs), which include Crohn\'s disease (CD) and ulcerative colitis (UC), are idiopathic and chronic inflammatory disorders of the gastrointestinal tract.[@B1] UC is characterized by inflammation that is limited to the mucosal and sub-mucosal layers of the colon and rectum. Conversely, in CD, the inflammation may involve any part of the gastrointestinal tract in a non-continuous fashion.[@B2] The incidence of IBD is increasing around the world, and its influence on morbidity and mortality are quite significant.[@B3] To date, the definite etiology of IBDs remains elusive. Nevertheless, growing evidence has indicated that IBDs result from a complicated inflammatory response in which environmental and genetic factors may play important roles.[@B4][@B5]

Toll-like receptors (TLRs) represent a group of pattern recognition receptors (PRRs) that can be activated through the recognition of pathogen-associated molecular patterns (PAMPs).[@B6] There are ten different TLRs that have been identified in humans, and TLR9 is one of them. TLR9 is characterized by recognizing unmethylated CpG DNA and acting as an effective sensor for bacterial infection.[@B7] Different from other TLRs, the PAMP recognition of TLR9 mainly takes place on the surface of the endosomal compartment. When CpG-DNA binds to TLR9, MyD88 is recruited, leading to phosphorylation of IRAK and TRAF6, at which point the transcription factor NF-κB is finally activated.[@B8] The gene encoding TLR9 is located on the chromosome 3p21.3, which is in the vicinity of one susceptible region for IBDs.[@B9] Numerous single nucleotide polymorphisms (SNPs) have been identified for the *TLR9* gene, and the -1237T/C polymorphism (rs5743836) is the most significant.[@B10][@B11][@B12] It has been proven that the rs5743836 T/C polymorphism can lead to a T-to-C exchange in the promoter region of *TLR9* at position -1237, which can create a potential binding site for NF-κB.[@B13]

A number of recent case-control studies have been carried out to evaluate the association between *TLR9*-1237T/C polymorphism and the susceptibility of IBDs.[@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21] However, the results are controversial. A meta-analysis is a powerful method to deal with these ambiguities and can enhance the statistical power of genetic association studies.[@B22] Thus, we performed this meta-analysis to determine the exact relationship between *TLR9*-1237T/C polymorphism and the risk of IBDs.

MATERIALS AND METHODS
=====================

Search strategy
---------------

A comprehensive search was conducted for this meta-analysis on the association between *TLR9*-1237T/C polymorphism and IBDs without language restrictions. Relevant publications were selected using the following electronic databases: PubMed, Web of Knowledge, and the Chinese National Knowledge Infrastructure (CNKI), with the most recent report dated February, 2015. The following terms were used as search keywords: (\"TLR9\" or \"Toll-like receptor 9\"), (\"polymorphism,\" \"variant,\" or \"SNP\"), and (\"inflammatory bowel disease,\" \"Crohn\'s disease,\" \"ulcerative colitis,\" \"IBD,\" \"CD,\" or \"UC\"). The reference list of all retrieved literature was carefully scanned to identify the relevant publications.

Inclusion and exclusion criteria
--------------------------------

Studies were included in this meta-analysis if they met all of the following criteria: 1) evaluation of the association between *TLR9*-1237T/C polymorphism and the risk of IBDs; 2) a case-control design; 3) genotype distribution availability in cases and controls; and 4) consistency of the genotype distributions in the controls with Hardy-Weinberg equilibrium (HWE). Studies were excluded if they met any one of the following criteria: 1) genotype or allele frequencies could not be obtained; 2) duplicated data were used; or 3) data were only presented in reviews, case-reports, or abstracts.

Data extraction
---------------

Two authors (Jian Shang & Xiaobing Wang) of this article independently extracted the data from the eligible literature. Discrepancies between the reviewers were solved by discussion or a third author. The following extracted data were included: first author\'s name, publication year, region, ethnicity, source of control, genotyping method, number of cases and controls, and *p*-value for HWE. Furthermore, corresponding authors were contacted if the genotype or allele frequencies were not immediately available.

Quality score assessment
------------------------

The quality of each study was independently assessed by two authors (Jian Shang & Liping Chen) of our study. The quality scoring criteria in this meta-analysis was modified from previous publications ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, only online).[@B23][@B24] Total quality scores ranged from 0 points (worst) to 14 points (best).

Statistical analysis
--------------------

RevMan 5.2 (Cochrane Collaboration, Copenhagen, Denmark) and STATA 12.0 (Stata Corp., College Station, TA, USA) were used to conduct this meta-analysis. The strength of the association between *TLR9*-1237T/C polymorphism and the risk of IBDs was estimated using pooled odds ratios (ORs) and 95% confidence intervals (CIs). Five different genetic models were performed in our study: a dominant model (TC+CC vs. TT), a recessive model (CC vs. TC+TT), heterozygote comparison (TC vs. TT), homozygote comparison (CC vs. TT), and an allele model (C vs. T). Heterogeneity was estimated using Cochran\'s Q statistic and I^2^ statistic; I^2^ values of 25%, 50%, and 75% were defined as low, moderate, and high heterogeneity, respectively.[@B25] If the *p*-value of the Q-test was \>0.05 or the I^2^ value was ≤50%, the pooled ORs of each study were calculated using a fixed-effective model. Otherwise, a random-effective model was used.[@B26] Publication bias was calculated using a funnel plot and Egger\'s test.[@B27] A χ^2^ test was performed to assess whether the genotype distributions in the control groups conformed to HWE. In addition, subgroup analyses stratified by ethnicity and disease phenotype were also conducted in our study.

RESULTS
=======

Literature retrieval and characteristics of eligible studies
------------------------------------------------------------

A detailed flow diagram of literature retrieval is shown in [Fig. 1](#F1){ref-type="fig"}. After an initial comprehensive search from the selected databases, 485 articles were initially identified in our study. Among these, 266 were found to contain duplicated data. After screening the remaining 219 papers by reading the titles and abstracts, 12 studies were assessed in more detail. After reading the full texts of these studies, we excluded one paper with incomplete data and three papers with incorrect polymorphism. Ultimately, a total of eight studies assessing the association between *TLR9*-1237T/C polymorphism and the risk of IBDs were available in the current meta-analysis. Among these, six were performed in Caucasian populations, and two were in Asian populations. Numerous genotyping methods were used in these studies, including single-direction-sequencing (SDS), TaqMan, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and matrix-assisted laser desorption/ionization time of flight (MALDI-TOF). Genotype distributions were all in accordance with HWE ([Table 1](#T1){ref-type="table"}). The precise characteristics of the selected literature are shown in [Table 1](#T1){ref-type="table"}, and the genotype and allele distributions of cases and controls are summarized in [Table 2](#T2){ref-type="table"}.

Quantitative data synthesis
---------------------------

A summary of the meta-analysis of the relationship between *TLR9*-1237T/C polymorphism and the risk of IBDs is shown in [Table 3](#T3){ref-type="table"}. Overall, significant association was found between *TLR9*-1237T/C polymorphism and IBDs using recessive (OR: 1.59; 95% CI: 1.02-2.47; *p*=0.04) ([Fig. 2](#F2){ref-type="fig"}) and homozygote (OR: 1.62; 95% CI: 1.04-2.52; *p*=0.03) ([Fig. 2](#F2){ref-type="fig"}) genetic models. Additionally, we also found a borderline-significant association of *TLR9*-1237T/C polymorphism with the risk of IBDs using the allele model (OR: 1.13; 95% CI: 1.00-1.27; *p*=0.05) ([Fig. 2](#F2){ref-type="fig"}).

In order to clarify the potential difference in ethnicity, a subgroup analysis stratified by population group was performed in our study. Similarly, in Caucasians, there was significant or borderline-significant association between *TLR9*-1237T/C polymorphism and the risk of IBDs based on recessive (OR: 1.59; 95% CI: 1.02-2.47; *p*=0.04) ([Fig. 3](#F3){ref-type="fig"}), homozygote (OR: 1.62; 95% CI: 1.04-2.52; *p*=0.03) ([Fig. 4](#F4){ref-type="fig"}), and allele (OR: 1.12; 95% CI: 1.00-1.27; *p*=0.05) ([Fig. 5](#F5){ref-type="fig"}) models. However, no significant association was found among Asian populations.

In the subgroup analysis stratified by clinical type, significant association of *TLR9*-1237T/C polymorphism with CD risk was found using recessive (OR: 1.69; 95% CI: 1.05-2.73; *p*=0.03) ([Fig. 6](#F6){ref-type="fig"}), homozygote (OR: 1.74; 95% CI: 1.07-2.82; *p*=0.02) ([Fig. 7](#F7){ref-type="fig"}) and allele (OR: 1.15; 95% CI: 1.01-1.32; *p*=0.04) ([Fig. 8](#F8){ref-type="fig"}) genetic models. Unfortunately, we failed to find any statistical evidence of association between *TLR9*-1237T/C polymorphism and risk of disease in the UC subgroup when all contrasts were performed.

Evaluation of heterogeneity
---------------------------

As shown in [Table 3](#T3){ref-type="table"}, there was no inter-study heterogeneity among the overall studies of *TLR9*-1237T/C polymorphism for all five genetic models (dominant model: Q=7.08, *p*=0.42, I^2^=1%; recessive model: Q=1.48, *p*=0.92, I^2^=0%; heterozygote comparison: Q=6.13, *p*=0.52, I^2^=0%; homozygote comparison: Q=1.85, *p*=0.87, I^2^=0%; allele model: Q=7.47, *p*=0.38, I^2^=6%). Therefore, the fixed-effective model was used in our meta-analysis.

Publication bias
----------------

Potential publication bias was estimated by evaluating the funnel plot\'s shape and Egger\'s test in this meta-analysis. Egger\'s linear regression test showed a moderate publication bias for the recessive model (CC vs. TT+TC) in the UC subgroup (*p*=0.019); however, no evidence of publication bias was found for any other genetic models in the overall studies and subgroups ([Table 3](#T3){ref-type="table"}, [Fig. 9](#F9){ref-type="fig"}).

DISCUSSION
==========

The two major clinical types of IBDs, CD, and UC, are complicated and recurrent intestinal inflammatory disorders that are closely related to the susceptibility of colon cancer.[@B28] CD is characterized by a transmural inflammation of the entire gastrointestinal tract. However, the inflammation of UC is non-transmural and mainly restricted to the colon.[@B2] It has always been considered that IBDs result from an inappropriate inflammatory response to gut microbes in genetically susceptible hosts. Meanwhile, the characteristic of familiar aggregation may indicate a common genetic background across IBDs.[@B29] To date, numerous genetic studies have significantly advanced our understanding of the pathogenesis of IBDs, and many susceptible genes have been identified.[@B30],[@B31],[@B32] Among them, *TLR9* gene has been highlighted.

TLR9 is a PRR of the TLR family that can mediate the innate immunity by specifically recognizing the CpG motifs of bacteria DNA.[@B7] The TLR9 gene, located on chromosome 3p21.3, has numerous polymorphisms on its promoter region, and the -1237T/C polymorphism has been mostly studied.[@B9][@B10][@B11][@B12] Accumulating evidence has suggested that *TLR9*-1237T/C polymorphism is associated with multiple inflammatory diseases including asthma,[@B33] systemic lupus erythematosus (SLE),[@B34] and rheumatoid arthritis (RA).[@B35] Recently, a number of case-control studies have been published to illustrate the association of *TLR9*-1237T/C polymorphism with the susceptibility of IBDs; however, the results are contradictory.[@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21] Thus, we thoroughly searched for research on this topic and performed this meta-analysis. To our knowledge, this is the first comprehensive meta-analysis that attempts to determine the exact relationship between *TLR9*-1237T/C polymorphism and risk of IBDs.

A total of eight publications including 2987 cases and 2388 controls were retrieved in our meta-analysis. The impacts of dominant, recessive, heterozygote, homozygote, and allele genetic models were all evaluated. In addition, considering that the differences in genetic background may have influenced the outcome of the genetic association studies, we also conducted subgroup analyses stratified by ethnicity and disease type. Overall, our results indicated that *TLR9*-1237T/C polymorphism might act as a risk factor in IBDs. In the recessive model, the risk of IBDs in individuals with CC genotype was 1.59-fold higher than those with TT+TC genotype. On homozygote comparison, the risk of individuals with CC genotype was 1.62-fold higher than the TT carriers. Moreover, our study also suggested an increased risk of IBDs with C allele carriers compared to the T allele carriers, although the discrepancy was only borderline significant (*p*=0.05).

There were two types of populations in our meta-analysis: Caucasians and Asians. Our data suggested that there was a significant difference between the two ethnicities in the association between *TLR9*-1237T/C polymorphism and IBD risk. Among the studies involving Caucasians, we found a significant association between rs5743836 T/C polymorphism and the risk of IBDs using the recessive model and homozygote comparison. Furthermore, a borderline-significant association of *TLR9*-1237T/C polymorphism with IBDs was also found in the allele model. On the other hand, there was no statistical evidence for the association between *TLR9*-1237T/C polymorphism and the susceptibility of IBDs in Asians.

Considering that the potential clinical type discrepancy might influence the genotype distribution, we then performed the subgroup analyses stratified by disease phenotype. Eight studies were included in the CD subgroup, and our study indicated a pathogenic role of *TLR9*-1237T/C polymorphism in the development of CD. These results suggested that individuals with CC genotype might have higher risk of CD than those with TT+TC and TT genotypes. Moreover, the risk of CD was also increased in C allele carriers. However, there was no association between *TLR9*-1237T/C polymorphism and the susceptibility of UC.

As mentioned above, one published dataset indicated that the *TLR9*-1237T/C polymorphism could lead to a T to C exchange at the position -1237 of the *TLR9* gene promoter, which would provide a binding site for transcript factor NF-κB.[@B13] Hence, we speculate that the *TLR9*-1237T/C polymorphism may influence the susceptibility of IBDs by affecting the transcription of NF-κB. The findings in the subgroup analyses by ethnicity and clinical type were not consistent, suggesting that the association between *TLR9*-1237T/C polymorphism and risk of IBDs was ethnicity- and disease-specific.

Heterogeneity is a limitation that exists in meta-analyses and may reduce the statistical power and distort the final results. Thus, we performed a χ^2^-test-based Q test to assess the interstudy heterogeneity in our meta-analysis. Interestingly, there was no evidence of existing heterogeneity among overall study data or subgroup data using all five genetic models. Regarding publication bias, the funnel plot shapes for all five comparisons of overall studies, CD subgroups, Caucasian populations, and Asian populations were symmetrical, and Egger\'s test similarly did not provide any statistical evidence of publication bias ([Table 3](#T3){ref-type="table"}). However, there was moderate publication bias in the UC subgroup towards using the recessive model, which may have distorted our results.

Results in the present meta-analysis should be interpreted with caution due to the following limitations. Firstly, the number of studies and individuals were relatively small in our study, which would reduce the statistical power of the meta-analysis determining the relationship between *TLR9*-1237T/C polymorphism and IBD risk. Secondly, publication bias existed in several comparisons, and this may have distorted our results, as several studies with negative results may have been ignored or may not have been published. Thirdly, we only included literature that was focused on Caucasians and Asians, and future studies should contain more ethnicities.

In summary, our results remain significant despite these limitations. The findings from the present meta-analysis indicated that the *TLR9*-1237T/C polymorphism might act as a risk factor in the development of IBDs, particularly in Caucasians. Furthermore, our study also suggested a pathogenic role of this polymorphism in the development of CD. However, more large-scaled case-control studies are needed to further confirm our conclusions.
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![Forest plot for the meta-analysis of the association between *TLR9* -1237T/C polymorphism and the susceptibility of IBDs stratified by ethnicity (recessive model). CI, confidence interval; IBD, inflammatory bowel disease.](ymj-57-153-g003){#F3}

![Forest plot for the meta-analysis of the association between *TLR9* -1237T/C polymorphism and the susceptibility of IBDs stratified by ethnicity (homozygote comparison). CI, confidence interval; IBD, inflammatory bowel disease.](ymj-57-153-g004){#F4}

![Forest plots for the meta-analysis of the association between *TLR9* -1237T/C polymorphism and the susceptibility of IBD stratified by ethnicity (allele model). CI, confidence interval; IBD, inflammatory bowel disease.](ymj-57-153-g005){#F5}

![Forest plot for the meta-analysis of the association between *TLR9* -1237T/C polymorphism and the susceptibility of IBDs stratified by clinical type (recessive model). CI, confidence interval; IBD, inflammatory bowel disease; CD, Crohn\'s disease; UC, ulcerative colitis.](ymj-57-153-g006){#F6}

![Forest plot for the meta-analysis of the association between *TLR9* -1237T/C polymorphism and the susceptibility of IBDs stratified by clinical type (homozygote comparison). CI, confidence interval; IBD, inflammatory bowel disease; CD, Crohn\'s disease; UC, ulcerative colitis.](ymj-57-153-g007){#F7}

![Forest plot for the meta-analysis of the association between *TLR9* -1237T/C polymorphism and the susceptibility of IBDs stratified by clinical type (allele model). CI, confidence interval; IBD, inflammatory bowel disease; CD, Crohn\'s disease; UC, ulcerative colitis.](ymj-57-153-g008){#F8}

![Funnel plots for *TLR9* -1237T/C polymorphism and IBDs: (A) dominant model, (B) recessive model, (C) heterozygote comparison, (D) homozygote comparison, and (E) allele model. Each point represents a separate study for the indicated association. SE, standardized effect; IBD, inflammatory bowel disease; OR, odds ratio.](ymj-57-153-g009){#F9}

###### Characteristics of the References Included in Our Meta-Analysis
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author              Year   Region        Ethnicity   Source of control   Genotyping method   Cases (n)   Controls (n)   HWE\          Quality score           
                                                                                                                                (*p* value)                           
  ------------------------- ------ ------------- ----------- ------------------- ------------------- ----------- -------------- ------------- --------------- ------- ----
  Hong[@B21]                2007   New Zealand   Caucasian   PB                  PCR-RFLP            182         182            \-            188             0.052   11

  Hotte[@B20]               2012   Canada        Caucasian   HB                  SDS                 29          15             14            21              0.512   8

  Petermann[@B19]           2009   New Zealand   Caucasian   PB                  Taqman              793         387            406           412             0.641   13

  Shen[@B18]                2010   China         Asian       HB                  PCR-RFLP            113         30             83            120             0.963   10

  Török[@B16]               2004   Germany       Caucasian   PB                  PCR-RFLP            312         174            138           265             0.662   10

  Török[@B17]               2009   Germany       Caucasian   PB                  PCR-RFLP            953         605            348           792             0.239   13

  Valverde-Villegas[@B15]   2014   Brazil        Caucasian   PB                  PCR-RFLP            239         132            107           239             0.893   11

  Ye[@B14]                  2009   Korea         Asian       PB                  MALDI-TOF           366         366            \-            351             0.978   12
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PB, population-based; HB, hospital-based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; SDS, single-direction-sequencing; MALDI-TOF, matrix-assisted laser desorption/ionization time of flight; IBD, inflammatory bowel disease; CD, Crohn\'s disease; UC, ulcerative colitis; HWE, Hardy-Weinberg equilibrium.

###### Genotype and Allele Distributions of *TLR9* -1237T/C Polymorphism in Cases and Controls
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  References                        IBD   CD    UC   Control   IBD   CD   UC    Control                                                                      
  --------------------------------- ----- ----- ---- --------- ----- ---- ----- --------- ---- ----- ----- ---- ------ ----- ------ ----- ----- ----- ------ -----
  Hong, et al.[@B21]                130   50    2    130       50    2    \-    \-        \-   131   56    1    310    54    310    54    \-    \-    318    58
  Hotte, et al.[@B20]               21    6     2    11        4     0    10    2         2    15    5     1    48     10    26     4     22    6     35     7
  Petermann, et al.[@B19]           572   200   21   282       94    11   290   106       10   291   112   9    1344   242   658    116   686   126   694    130
  Shen, et al.[@B18]                110   3     0    29        1     0    81    2         0    119   1     0    223    3     59     1     164   2     239    1
  Török, et al.[@B16]               216   86    10   114       53    7    102   33        3    205   57    3    518    106   281    67    237   39    467    63
  Török, et al.[@B17]               691   245   17   435       159   11   256   86        6    593   189   10   1627   279   1029   181   598   98    1375   209
  Valverde-Villegas, et al.[@B15]   159   69    11   86        39    7    73    30        4    171   62    6    387    91    211    53    176   38    404    74
  Ye, et al.[@B14]                  366   0     0    366       0     0    \-    \-        \-   350   1     0    732    0     732    0     \-    \-    701    1

IBD, inflammatory bowel disease; CD, Crohn\'s disease; UC, ulcerative colitis.

###### Total and Subgroup Analyses of *TLR9* -1237T/C Polymorphism in IBDs
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Total or subgroup studies   Comparisons    Sample size   N      Test of association   Model   Test of heterogeneity   Eggers\' test\                                   
                                                                                                                        (*p* value)                                      
  --------------------------- -------------- ------------- ------ --------------------- ------- ----------------------- ---------------- ------ ---- ------ ------ ----- -------
  Total                       TC+CC vs. TT   2987          2388   8                     1.11    \[0.97, 1.27\]          1.54             0.12   F    7.08   0.42   1%    0.533

                              CC vs. TC+TT   2987          2388   8                     1.59    \[1.02, 2.47\]          2.06             0.04   F    1.48   0.92   0%    0.688

                              TC vs. TT      2924          2358   8                     1.08    \[0.94, 1.24\]          1.08             0.28   F    6.13   0.52   0%    0.612

                              CC vs. TT      2328          1905   8                     1.62    \[1.04, 2.52\]          2.14             0.03   F    1.85   0.87   0%    0.693

                              C vs. T        5974          4776   8                     1.13    \[1.00, 1.27\]          1.95             0.05   F    7.47   0.38   6%    0.466

  Caucasian                   TC+CC vs. TT   2508          1917   6                     1.11    \[0.97, 1.27\]          1.5              0.13   F    5.64   0.34   11%   0.719

                              CC vs. TC+TT   2508          1917   6                     1.59    \[1.02, 2.47\]          2.06             0.04   F    1.48   0.92   0%    0.688

                              TC vs. TT      2445          1887   6                     1.08    \[0.94, 1.23\]          1.04             0.3    F    4.67   0.46   0%    0.697

                              CC vs. TT      1852          1436   6                     1.62    \[1.04, 2.52\]          2.14             0.03   F    1.85   0.87   0%    0.693

                              C vs. T        5016          3834   6                     1.12    \[1.00, 1.27\]          1.93             0.05   F    6.05   0.3    17%   0.741

  Asian                       TC+CC vs. TT   479           471    2                     1.44    \[0.28, 7.26\]          0.44             0.66   F    1.34   0.25   25%   NA

                              CC vs. TC+TT   479           471    2                     \-      \-                      \-               \-     \-   \-     \-     \-    \-

                              TC vs. TT      479           471    2                     1.44    \[0.28, 7.26\]          0.44             0.66   F    1.34   0.25   25%   NA

                              CC vs. TT      476           469    2                     \-      \-                      \-               \-     \-   \-     \-     \-    \-

                              C vs. T        958           942    2                     1.43    \[0.28, 7.22\]          0.44             0.66   F    1.33   0.25   25%   NA

  CD                          TC+CC vs. TT   1891          2388   8                     1.14    \[0.98, 1.32\]          1.68             0.09   F    9.7    0.21   28%   0.556

                              CC vs. TC+TT   1891          2388   8                     1.69    \[1.05, 2.73\]          2.14             0.03   F    2.54   0.77   0%    0.364

                              TC vs. TT      1853          2358   8                     1.1     \[0.94, 1.29\]          1.22             0.22   F    8.23   0.31   15%   0.7

                              CC vs. TT      1491          1905   8                     1.74    \[1.07, 2.82\]          2.25             0.02   F    3.11   0.68   0%    0.403

                              C vs. T        3782          4776   8                     1.15    \[1.01, 1.32\]          2.1              0.04   F    10.5   0.16   33%   0.902

  UC                          TC+CC vs. TT   1096          1849   6                     1.07    \[0.89, 1.27\]          0.71             0.48   F    1.52   0.91   0%    0.53

                              CC vs. TC+TT   1096          1849   6                     1.41    \[0.82, 2.45\]          1.24             0.22   F    0.84   0.93   0%    0.019

                              TC vs. TT      1071          1820   6                     1.04    \[0.87, 1.25\]          0.43             0.67   F    1.7    0.89   0%    0.835

                              CC vs. TT      837           1423   6                     1.42    \[0.82, 2.46\]          1.24             0.22   F    0.8    0.94   0%    0.057

                              C vs. T        2192          3698   6                     1.08    \[0.92, 1.27\]          0.98             0.32   F    1.77   0.88   0%    0.277
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N, number of the comparisons; OR, odds ratio; CI, confidence interval; F, fixed-effective model; IBD, inflammatory bowel disease; CD, Crohn\'s disease; UC, ulcerative colitis; NA, not applicable.
